By Fineline Cube Sino Biopharmaceutical (HKG: 1177) announced that TQB3454 Tablets, a Category 1 innovative drug developed by subsidiary Chia Tai Tianqing (CTTQ), achieved pre-defined superiority margins on both Progression-Free Survival (PFS) and Overall Survival (OS) in a pre-specified interim analysis of its Phase III study in advanced biliary tract cancer (BTC) with IDH1 mutations. The Independent Data Monitoring Committee (IDMC) recommended proceeding, and CTTQ has received CDE written consent to submit the NDA, positioning TQB3454 as the world’s second and China’s first IDH1 inhibitor to demonstrate Phase III success in this indication.
Phase III Interim Analysis Results
| Endpoint | Result | Significance |
|---|---|---|
| Progression-Free Survival (PFS) | Met pre-defined superiority margin | Primary endpoint achievement |
| Overall Survival (OS) | Met pre-defined superiority margin | Primary endpoint achievement |
| IDMC Recommendation | Continue study / Proceed to NDA | Independent validation of efficacy |
| Regulatory Status | CDE written consent received | NDA submission imminent |
Study Population: Advanced biliary tract cancer patients with IDH1 mutations
Product Profile
| Attribute | TQB3454 Specification |
|---|---|
| Mechanism | Selective IDH1 mutant enzyme inhibitor |
| Developer | Chia Tai Tianqing (CTTQ), Sino Biopharm subsidiary |
| Drug Class | Category 1 innovative drug (China) |
| Target Population | IDH1-mutant advanced biliary tract cancer |
| Global Positioning | World’s second IDH1 inhibitor with Phase III BTC success; China’s first |
Market Context & Strategic Impact
| Factor | Implication |
|---|---|
| BTC Incidence | ~180,000 new cases annually in China; 15–20% harbor IDH1 mutations (~27,000–36,000 addressable patients) |
| Unmet Need | No approved targeted therapies for IDH1-mutant BTC in China; standard of care (gemcitabine/cisplatin) offers limited survival benefit |
| Competitive Landscape | Ivosidenib (Servier) first global approval in BTC; TQB3454 positions as domestic alternative with potential cost advantage |
| Precision Oncology Trend | Validates CTTQ’s molecularly targeted strategy; builds IDH1 franchise for potential expansion to acute myeloid leukemia (AML) |
| Revenue Potential | Peak sales RMB 800 million–1.2 billion annually in China assuming NRDL inclusion and competitive pricing |
- Regulatory Pathway: NDA submission to NMPA CDE expected Q2 2026; priority review designation likely given unmet need and domestic innovation status
- Commercial Strategy: Leverage CTTQ’s oncology sales force (established in lung/GI cancers) for rapid hospital listing post-approval
Pipeline & Platform Validation
- IDH1 Portfolio: TQB3454 success validates CTTQ’s medicinal chemistry platform for mutant enzyme inhibitors; potential for combination studies with PD-1 inhibitors in BTC
- Global Rights: Sino Biopharm retains worldwide rights; ex-China partnership discussions anticipated post-China approval
Forward‑Looking Statements
This brief contains forward‑looking statements regarding NDA submission timelines, regulatory approval, and commercial projections for TQB3454. Actual results may differ due to CDE review duration, competitive dynamics with ivosidenib, and reimbursement negotiations.-Fineline Info & Tech